This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Forget Zimmer Biomet (ZBH), Buy These 3 Medical Devices Stocks
by Urmimala Biswas
With orthopedic stocks like Zimmer Biomet (ZBH) are grappling with several issues, it is wise to invest in medical device stocks like TMO, NEOG and CERN instead for 2022.
Neogen (NEOG) Q2 Earnings Miss Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -41.18% and 1.10%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to NEOGEN (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about NEOGEN (NEOG) given robust sales growth in the Food Safety business and impressive international performance.
NEOGEN (NEOG) Gains on 3M's Food Safety Arm Merger Deal
by Zacks Equity Research
According to NEOGEN (NEOG), apart from the United States and Europe, substantial interest among developing nations to improve food safety presents significant growth potential for the combined company.
3M (MMM) to Divest Food Safety to NEOGEN in Tax-Friendly Deal
by Zacks Equity Research
3M's (MMM) food safety business combined with NEOGEN will create a global leader in the food security market, with expanded offerings, market presence and innovation capabilities.
Company News for Dec 15, 2021
by Zacks Equity Research
Companies In The News Are: TSLA, TMX, NEOG, MMM, PFE.
Neogen (NEOG) Soars 8.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Neogen (NEOG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NEOGEN (NEOG) Inks Deal to Boost Global Genomics Business
by Zacks Equity Research
NEOGEN's (NEOG) latest acquisition of Genetic Veterinary Sciences, Inc. will bolster the global genomics business.
NEOGEN (NEOG) Strengthens Global Foothold With Delf Buyout
by Zacks Equity Research
NEOGEN (NEOG) management believes that Delf's 40 years of experience in the UK dairy hygiene market will help it strengthen its foothold in this region's dairy chemicals market.
Veru Inc. (VERU) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of 37.50% and 14.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Add Neogen (NEOG) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Neogen (NEOG) on strength in its Food Safety and Animal Safety business segments.
Thermo Fisher (TMO) Expands Biologics Network With New Facility
by Zacks Equity Research
Thermo Fisher's (TMO) Lengnau site will offer biopharma companies a pathway from development to large-scale production.
NEOGEN (NEOG) Inks Genomic Selection Deal With Hendrix
by Zacks Equity Research
Hendrix Genetics with the help of NEOGEN's (NEOG) Genomics will be able to genotype the elite animals in the population.
NEOGEN (NEOG) Igenity Branded Calves Score Highest US Sales
by Zacks Equity Research
NEOGEN's (NEOG) Igenity-tested calves earn an average premium of over $59 in the summer selling season.
All You Need to Know About Neogen (NEOG) Rating Upgrade to Buy
by Zacks Equity Research
Neogen (NEOG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neogen (NEOG) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Strong segmental performance and contributions from new acquisitions and product launches drove Neogen's (NEOG) revenues in the first quarter of fiscal 2022.
Company News for Sep 22, 2021
by Zacks Equity Research
Companies In The News Are: UBER, ATVI, AZO, NEOG.
Neogen (NEOG) to Report Q1 Results: What You Should Expect
by Zacks Equity Research
Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEOGEN (NEOG) to Enter Retail Parasiticide Space With New Buyout
by Zacks Equity Research
NEOGEN's (NEOG) acquisition of CAPInnoVet expands its Animal Safety division and offers a strategic entry into the retail parasiticide market.
Neogen (NEOG) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of 6.67% and 4.82%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Down 4.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Strong fiscal fourth-quarter performance in the Food Safety and Animal Safety segments drove the top line for Neogen (NEOG).
Neogen (NEOG) Misses Q4 Earnings, Tops Revenue Estimates
by Zacks Equity Research
Strong segmental revenues and solid international performance across Neogen's (NEOG) entire business drove its topline.
Neogen (NEOG) Lags Q4 Earnings Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -6.25% and 2.02%, respectively, for the quarter ended May 2021. Do the numbers hold clues to what lies ahead for the stock?